Lisanti资本增长有限责任公司投资660 000美元给LENZ治疗公司,这是一家进行视力治疗试验的生物制药公司。 Lisanti Capital Growth LLC invested $660,000 in LENZ Therapeutics, a biopharm company in vision therapy trials.

投资公司Lisanti资本成长有限公司最近购买了价值660 000美元的LENZ治疗药物,这是一家生物制药公司,市场上限为8.4957亿美元。 Investment firm Lisanti Capital Growth LLC has recently bought $660,000 worth of LENZ Therapeutics, a biopharmaceutical company with a market cap of $849.57 million. 开发改善视力疗法的LENZ治疗药物于星期一开放,其库存为30.18美元。 LENZ Therapeutics, which develops vision improvement therapies, saw its stock open at $30.18 on Monday. 该公司的产品候选人正在接受第三阶段临床试验,过去一年的库存在16.54美元和43.50美元之间。 The company’s product candidates are in Phase III clinical trials, and its stock has varied between $16.54 and $43.50 over the past year.